32.39

3.08% -1.03

After Hours: 32.39

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $32.39, with a volume of 809.59K. It is down -3.08% in the last 24 hours and down -8.68% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$33.42

Open:

$33.42

24h Volume:

809.59K

Relative Volume:

1.29

Market Cap:

$1.86B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

15.35

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

-10.00%

1M Performance:

-8.68%

6M Performance:

-3.60%

1Y Performance:

-14.22%

1-Day Range:

$32.30

$33.42

1-Week Range:

$32.30

$37.05

52-Week Range:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	32.39	1.91B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Sep 12, 2025

Adage Capital Partners GP L.L.C. Has $5.58 Million Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Sep 12, 2025

Petrus Trust Company LTA Invests $381,000 in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Sep 12, 2025

Harmony Biosciences stock price target raised to $50 by UBS on Zygel sales - Investing.com Canada

Sep 12, 2025